AU2018262811B2 - Secretion-competent muteins of the human IL-27 alpha-subunit - Google Patents

Secretion-competent muteins of the human IL-27 alpha-subunit Download PDF

Info

Publication number
AU2018262811B2
AU2018262811B2 AU2018262811A AU2018262811A AU2018262811B2 AU 2018262811 B2 AU2018262811 B2 AU 2018262811B2 AU 2018262811 A AU2018262811 A AU 2018262811A AU 2018262811 A AU2018262811 A AU 2018262811A AU 2018262811 B2 AU2018262811 B2 AU 2018262811B2
Authority
AU
Australia
Prior art keywords
leu
arg
pro
subunit
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018262811A
Other languages
English (en)
Other versions
AU2018262811A1 (en
Inventor
Matthias Feige
Stephanie Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technical University of Munich
Original Assignee
Technical University of Munich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technical University of Munich filed Critical Technical University of Munich
Publication of AU2018262811A1 publication Critical patent/AU2018262811A1/en
Application granted granted Critical
Publication of AU2018262811B2 publication Critical patent/AU2018262811B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018262811A 2017-05-04 2018-05-04 Secretion-competent muteins of the human IL-27 alpha-subunit Active AU2018262811B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17169358.3 2017-05-04
EP17169358 2017-05-04
PCT/EP2018/061561 WO2018202876A1 (en) 2017-05-04 2018-05-04 Secretion-competent muteins of the human il-27 alpha-subunit

Publications (2)

Publication Number Publication Date
AU2018262811A1 AU2018262811A1 (en) 2019-12-19
AU2018262811B2 true AU2018262811B2 (en) 2021-10-21

Family

ID=58669684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018262811A Active AU2018262811B2 (en) 2017-05-04 2018-05-04 Secretion-competent muteins of the human IL-27 alpha-subunit

Country Status (7)

Country Link
US (1) US11358998B2 (enExample)
EP (1) EP3619228A1 (enExample)
JP (1) JP7249955B2 (enExample)
CN (1) CN110709413B (enExample)
AU (1) AU2018262811B2 (enExample)
CA (1) CA3060219A1 (enExample)
WO (1) WO2018202876A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
WO2021094435A2 (en) * 2019-11-12 2021-05-20 Technische Universität München Homogeneous muteins of the human il-27 alpha-subunit
CN113307861A (zh) * 2020-12-09 2021-08-27 重庆医科大学 细胞因子il-27作为nec与fpies鉴别诊断标志物及应用
EP4695283A1 (en) * 2023-04-14 2026-02-18 Technische Universität München, in Vertretung des Freistaats Bayern Method for producing the subunits of human interleukin 35 from interleukin 12 and interleukin 27
CN116832146B (zh) * 2023-06-30 2024-02-13 广东暨安特博生物科技有限公司 Il-27蛋白在制备治疗阿尔茨海默症的产品的应用
CN122555718A (zh) * 2023-12-27 2026-08-11 上海药明生物技术有限公司 重组il-27蛋白及其制备方法
WO2025252853A1 (en) * 2024-06-04 2025-12-11 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Fusion-polypeptide comprising a mutein of the alpha-subunit of human il-27 and at least one pharmaceutically acceptable fusion partner

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4839434B2 (ja) * 2005-03-14 2011-12-21 千葉県 ｐ２８分子またはその遺伝子を含む医薬製剤
HK1206764A1 (en) * 2012-03-26 2016-01-15 Axcella Health Inc. Nutritive proteins and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JASON S STUMHOFER ET AL, "A role for IL-27p28 as an antagonist of gp130-mediated signaling", NATURE IMMUNOLOGY, (2010-11-07), vol. 11, no. 12, doi:10.1038/ni.1957, ISSN 1529-2908, pages 1119 - 1126 *
OSAMU SHIMOZATO ET AL, "The secreted form of p28 subunit of interleukin (IL)-27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses", IMMUNOLOGY, GB, (2009-09-01), vol. 128, no. 1pt2, pages e816 - e825 *
PFLANZ S ET AL, "IL-27 a heterodimetric cytokine composed of EB13 and p28 protein, induces proliferation of native CD4+ T cells", IMMUNITY, CELL PRESS, US, (2002-06-01), vol. 16, pages 779 - 790 *

Also Published As

Publication number Publication date
AU2018262811A1 (en) 2019-12-19
US20200062817A1 (en) 2020-02-27
CN110709413A (zh) 2020-01-17
EP3619228A1 (en) 2020-03-11
JP7249955B2 (ja) 2023-03-31
CN110709413B (zh) 2023-11-28
WO2018202876A1 (en) 2018-11-08
JP2020518249A (ja) 2020-06-25
CA3060219A1 (en) 2018-11-08
US11358998B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
US11358998B2 (en) Cretion-competent muteins of the human IL-27 alpha-subunit
EP3721892A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
JP2023518443A5 (enExample)
JPH10502810A (ja) Ｌｅｒｋ−５と命名された新規のサイトカイン
Liu et al. Release of the neuregulin functional polypeptide requires its cytoplasmic tail
Guo et al. Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region
Müller et al. An interspecies analysis reveals molecular construction principles of interleukin 27
JP6320973B2 (ja) Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法
JP6000130B2 (ja) 新規なシグナルペプチドおよび組換えタンパク質の生成のためのその使用
US8658423B2 (en) Insulin-like growth factor II (IGF-II) binding factors
JP7751581B2 (ja) Ｉｌ－３７融合タンパク質及びその使用
US20220380426A1 (en) Homogeneous muteins of the human il-27 alpha-subunit
Darabi et al. Codon optimization, cloning and expression of the human Leukemia Inhibitory Factor (hLIF) in E. coli
EP4695283A1 (en) Method for producing the subunits of human interleukin 35 from interleukin 12 and interleukin 27
Breen et al. Partial sequence of the rat heavy neurofilament polypeptide (NF‐H) Identification of putative phosphorylation sites
Kitamura et al. CD45‐associated protein is a lymphocyte‐specific membrane protein expressed in two distinct forms
ATE247668T1 (de) Für den prostaglandinrezeptor kodierendes gen, damit transformierte zelle und dessen expressionsprodukt
Monteilhet et al. Cytoplasmic and periplasmic production of human apolipoprotein E in Escherichia coli using natural and bacterial signal peptides
US6537781B1 (en) Methods and compositions concerning canine interleukin 5
Klepp et al. Production of functional bovine IL-22 in a mammalian episomal expression system
Müller Folding and quality control of the interleukin 12 family cytokines interleukin 27 and interleukin 35
WO2025252853A1 (en) Fusion-polypeptide comprising a mutein of the alpha-subunit of human il-27 and at least one pharmaceutically acceptable fusion partner
Ratcliff Characterisation of Prodomains in the GDNF Family
INTERNALIZATION CXCR1 and CXCR2 Activation and Regulation
NZ761945B2 (en) Expression control using a regulatable intron

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)